Shape Therapeutics
Business Services · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
700 Dexter Ave N, Seattle, Washington, 9...Phone Number
(628) 333-5866Website
www.shapetx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Shape Therapeutics
Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. The company was founded in 2018 and is headquartered in Seattle, Washington.Explore more
Shape Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Shape Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Shape Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Shape Therapeutics
Shape Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Shape Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Shape Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Shape Therapeutics launches new products
Check out if Shape Therapeutics is spiking on competitors!
Earning: See what the market has to say on Shape Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Shape Therapeutics
Find more new buyers
Compare Similar Companies to Shape Therapeutics
Compare insights from companies similar to Shape Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Shape Therapeutics
<$5M
51-200
Private
$147.5M
2018
KP
Kenneth PrenticeHead Senior VP, Process Development & Manufacturing
Company Profile Activity
Activity Insights
Shape Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Shape Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Shape Therapeutics.
Shape Therapeutics financials insights
Gather financial insights about Shape Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$35.5M
2021
Series B
$112M
Shape Therapeutics Tech Stack
A closer look at the technologies used by Shape Therapeutics
Most Recent Scoops
Person-Based
Left Company
Executive Move
David Huss, Interim Chief Executive Officer, has recently left the organization and now serves as Chief Technology Officer (Research) for Moderna.
Executive Moves, Left Company
Person-Based
Person-Based
Person-Based
Shape Therapeutics News & Media
Shape Therapeutics Announces Multiple Oral Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress
Shape Therapeutics to present at the ESGCT 32nd congress on an RNA-targeting gene therapy for Parkinson's Disease and a novel CNS AAV capsid.Shape Therapeutics Announces Multiple Oral and Poster Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress
Shape Therapeutics to present at the ESGCT 32nd congress on an RNA-targeting gene therapy for Parkinson's Disease and a novel CNS AAV capsid.Shape Therapeutics Presents Preclinical Data Highlighting Therapeutic Potential of RNA Editing and AAV Delivery Platforms at the American Society of Gene and Cell Therapy 28th Annual Meeting
Industry-leading RNA editing activity in the CNS of both mice and non-human primates highlights the broad applicability and therapeutic potential of the RNAfix® platform in CNS diseasesShape Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
Data support potential of innovative gene therapy using novel RNA editing, paired with targeted AAV.ai delivery and scalable manufacturing platforms Data support potential of innovative gene therapy using novel RNA editing, paired with targeted AAV.ai delivery and scalable manufacturing platforms
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Shape Therapeutics
Sign Up For FreeTo access detailed company insights
Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufactu... Read More
